GRI 바이오 (GRI) 주가

GRI 바이오(GRI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.88 (+2.17%), 시가총액 $0.00B, PER (주가수익비율) 0.06, 52주 최저~최고 $0.20 ~ $5.55.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for b

핵심 지표

• 현재가: $1.88 (+2.17%)
• 시가총액: $0.00B
• PER (주가수익비율): 0.06
• 52주 최저~최고: $0.20 ~ $5.55
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

GRI 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

GRI 바이오 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.37
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문